Ann: AGM Presentation, page-6

I've asked the two performance questions.
1) Can you update on the IV trials for UTI and what is planned there, including relative effectiveness?
answer: so the UTI made sense, they did the lab/petri dish ecoli effectiveness with urine taken from the fast high dose and worked really well. But focus is on gel as that's the obvious no brainer go to market, in the mean time, they're working on the R327 components to narrow down on what's the most effective parts to do more development on UTI IV and they also see a big need in pneumonia treatment and also preventing spread from ventilators, big issue in hospitals and one company extremely interested in this issue. (me: I presume that there's not good spray anti microbial agents, as they'ed mentioned on Q below that things like iodine is a poison, whereas R327 is not supposed to be or classified as poison)
2) An obvious question regarding topical gel trials is if it's better than std care? Like of the 14 successes, if they had topical antibiotic, would it have been as good?
answer: several had already had treatment for those wounds and diabetics were already compromised in cel lregrowth so in a way, this result is considered very good indeed, as there's no spray on anti-biotic, just poisons like iodine/betadine.

Someone asked that if there's "raging success" with the topical/IV, can other modes/applications be fast tracked, especially the in face of a real need? Graham said you can at least go straight to phase 2/3 trials for starters. They did mention that phase 1 trials showed comprehensively the safety. Also with going to late stage trials/commercialisation is busy and expensive, so initial successes with immediate projects means external money would flow with subsequent applications.